What is a triple-agonist peptide, and which peptide is the main example?

A triple-agonist peptide is a single acylated peptide that activates three metabolic receptors — the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The canonical example, and the compound the term was effectively coined around, is retatrutide (LY3437943, Eli Lilly's discovery designation). It was first characterised pharmacologically by Coskun et al. in Cell Metabolism (2022) and then studied in a published Phase 2 human obesity trial (Jastreboff et al., NEJM 2023;389:514-526, PMID 37366315). Other experimental triagonists exist in the literature, but retatrutide is the one with the most published human data.

How is a triple agonist different from a mono- or dual-agonist?

The difference is simply how many receptors the single molecule engages. A mono-agonist activates one receptor — semaglutide acts on the GLP-1 receptor only. A dual-agonist (co-agonist) activates two — tirzepatide acts on the GIP and GLP-1 receptors. A triple agonist activates three — retatrutide adds the glucagon receptor to GIP and GLP-1. The added glucagon-receptor arm is studied for increasing energy expenditure (thermogenesis), whereas the GLP-1 and GIP arms mainly reduce appetite and improve insulin handling. In published trials, more receptor arms broadly corresponded to larger weight changes, though these are clinical benchmarks for the drug class, not claims about a research reagent.

Why do the three receptors in a metabolic triple agonist matter?

Each receptor contributes a distinct effect. The GLP-1 receptor arm suppresses appetite and slows gastric emptying. The GIP receptor arm — the dominant driver of the natural 'incretin effect' in humans (Nauck & Meier, Diabetes Obes Metab. 2018;20 Suppl 1:5-21) — augments glucose-dependent insulin secretion and adipose insulin sensitivity. The glucagon receptor arm is studied for stimulating thermogenesis in brown adipose tissue and raising metabolic rate (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037). Combining all three in one molecule is intended to pair reduced caloric intake with potentially increased caloric expenditure.

Is a triple agonist FDA-approved?

No. The leading metabolic triple agonist, retatrutide (LY3437943), remains an investigational compound as of 2026 — only Phase 2 data have been published and Phase 3 trials are ongoing. No triple-receptor agonist is FDA-approved for any indication (approved incretin drugs are mono-agonists like semaglutide or the dual-agonist tirzepatide). Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory use — not for human or animal administration. Trial data referenced here is published science for context, not a claim about what Titan's product does, and not medical advice.

triple agonist · unimolecular triagonist · research use only

What is a triple agonist? The three-receptor peptide class, explained.

Short answer: a triple agonist is a single molecule engineered to activate three different receptors at once. An 'agonist' is a molecule that binds a receptor and switches it on (the opposite of an antagonist, which blocks it); a 'triple agonist' — also called a unimolecular triagonist — carries that on-switch activity for three distinct receptor systems in one compound. In peptide research the term is used almost exclusively for one specific class: the GIP + GLP-1 + glucagon receptor triagonists, all three of which are G-protein-coupled receptors involved in nutrient-stimulated hormone signalling. The canonical, most-studied triple-agonist research compound is retatrutide (also known by its discovery designation LY3437943), first characterised in Coskun et al., Cell Metab. 2022;34:1234-1247 (DOI 10.1016/j.cmet.2022.07.013, PMID 35985340) as 'a novel triple glucagon, GIP, and GLP-1 receptor agonist,' and later studied in a published Phase 2 human obesity trial (Jastreboff AM et al., NEJM 2023;389:514-526, DOI 10.1056/NEJMoa2301972, PMID 37366315). This page is a plain-English definition and feeder to the mechanism cluster. Retatrutide is an investigational compound; Titan's product is a research-use-only reagent, not for human or animal use. Not medical or dosing advice.

Retatrutide research reagent — $199.99 (in stock)How retatrutide works (mechanism)

Agonist vs antagonist vs 'triple': the plain definition

A receptor agonist is a molecule that binds a receptor and activates it — producing the downstream signalling that receptor controls. An antagonist binds but blocks activation. A mono-agonist hits one receptor; a dual-agonist (co-agonist) hits two; a triple agonist (triagonist) hits three, all within a single molecule rather than a cocktail of three drugs. The engineering goal of a unimolecular triagonist is to combine complementary pharmacology in one peptide with one pharmacokinetic profile. In the incretin/metabolic field the three receptors are the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Coskun et al. (Cell Metab. 2022;34:1234-1247, PMID 35985340) describe retatrutide/LY3437943 as exactly this — a single peptide with balanced glucagon and GLP-1 activity and relatively higher GIP-receptor activity.

The three receptor arms in detail →

Receptor 1 — GLP-1: appetite and glucose control

GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone secreted from intestinal L-cells after eating. GLP-1 receptor agonism suppresses appetite via hypothalamic satiety circuits, slows gastric emptying, and stimulates glucose-dependent insulin secretion while suppressing glucagon in hyperglycaemia (Nauck MA, Meier JJ, Incretin hormones: their role in health and disease, Diabetes Obes Metab. 2018;20 Suppl 1:5-21, DOI 10.1111/dom.13129, PMID 29364588). GLP-1R agonism is the pathway behind the mono-agonist drugs semaglutide and liraglutide, and it forms the appetite-and-glycaemic backbone of any incretin triple agonist.

GLP-1 research peptides →

Receptor 2 — GIP: the incretin insulin driver

GIP (glucose-dependent insulinotropic polypeptide) is the other classical incretin, secreted by K-cells in the upper gut. In healthy humans GIP is actually the dominant driver of the 'incretin effect' — the observation that oral glucose triggers a 2-3× larger insulin response than the same glucose given intravenously (Nauck & Meier, Diabetes Obes Metab. 2018;20 Suppl 1:5-21). GIP receptor agonism augments glucose-dependent insulin secretion and enhances the insulin sensitivity and lipid-buffering capacity of white adipose tissue. In retatrutide, GIP-receptor activity is the highest-potency arm — approximately 8.9× more potent than the endogenous GIP ligand at the human GIP receptor (Jastreboff et al., NEJM 2023, Methods). GIP+GLP-1 together (without glucagon) is the dual-agonist design of tirzepatide.

Triple vs dual agonist (retatrutide vs tirzepatide) →

Receptor 3 — glucagon: the energy-expenditure arm that makes it 'triple'

The glucagon receptor (GCGR) is the third arm — and the one that turns a dual agonist into a triple agonist. Glucagon receptor agonism is studied not for appetite but for energy expenditure: a 2022 peer-reviewed review (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037, DOI 10.3389/fendo.2022.868037) summarised evidence that glucagon-receptor activation stimulates thermogenesis in brown adipose tissue and has been associated with enhanced metabolic rate in humans. Adding the glucagon arm to GIP+GLP-1 is the defining structural feature of the triple-agonist class: it pairs reduced caloric intake (GLP-1/GIP) with a potential increase in caloric expenditure (glucagon). No prior approved GLP-1 or GIP/GLP-1 drug engages this third receptor.

Peptides studied for fat loss (class overview) →

Mono vs dual vs triple: where each design sits

The receptor-target count is the whole taxonomy. Mono-agonist: one receptor — semaglutide (GLP-1 only). Dual-agonist / co-agonist: two receptors — tirzepatide (GIP + GLP-1). Triple agonist / triagonist: three receptors — retatrutide (GIP + GLP-1 + glucagon). In the published human trials, the magnitude of weight change tracked broadly with the number of receptor arms engaged: semaglutide ~−14.9% (STEP 1, NEJM 2021), tirzepatide ~−22.5% at the top dose (SURMOUNT-1, NEJM 2022), and retatrutide −24.2% at 12 mg over 48 weeks in its Phase 2 trial (NEJM 2023). Those are clinical-trial benchmarks for the drug class as published science — not a claim about Titan's research-use-only reagent.

Retatrutide vs tirzepatide vs semaglutide →

Why identity verification matters for a triagonist reagent

Triple-agonist peptides like retatrutide are acylated: a fatty diacid chain is conjugated to the peptide backbone to give the compound its long (~6-day) half-life via reversible albumin binding. That acyl modification is exactly what makes identity confirmation important — an unmodified or mis-acylated peptide can still show a high HPLC purity peak while being the wrong molecule with a completely different receptor profile. A meaningful check confirms the mass of the acylated species by mass spectrometry (ESI-MS), not purity alone. Titan supplies retatrutide with lot-matched, in-house release documentation (HPLC purity vs internal target + ESI-MS identity of the acylated species) on request. No third-party certificate is claimed — the honest, verifiable edge is a real lot-matched in-house release sheet.

Lot COA checklist for acylated peptides →

The detail, in plain terms

Triple agonist, at a glance.

Definitions and figures below summarise the published pharmacology of the incretin triple-agonist class, anchored on the retatrutide/LY3437943 literature. This is a research reference, not a class-efficacy or product claim. Research use only; not medical or human-use advice.

Definition — agonist: A molecule that binds a receptor and switches it ON (produces its downstream signalling). Opposite of an antagonist, which blocks it.
Definition — triple agonist (triagonist): A single molecule that activates THREE different receptors at once — 'unimolecular' because it is one compound, not three drugs combined.
The three receptors (metabolic triagonists): GIP receptor (GIPR) + GLP-1 receptor (GLP-1R) + glucagon receptor (GCGR). All are G-protein-coupled receptors involved in nutrient-stimulated hormone signalling.
Canonical triple-agonist compound: Retatrutide (LY3437943), first described as a triple GCGR/GIPR/GLP-1R agonist by Coskun et al., Cell Metab. 2022;34:1234-1247 (PMID 35985340).
GLP-1 arm — what it does: Appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion. The mono-agonist pathway (semaglutide).
GIP arm — what it does: Dominant driver of the human incretin effect; augments insulin secretion + adipose insulin sensitisation. Highest-potency arm in retatrutide (~8.9× endogenous GIP at human GIPR; NEJM 2023).
Glucagon arm — what it does: Energy-expenditure / thermogenesis via brown adipose tissue — the arm that distinguishes 'triple' from 'dual' (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037).
Mono vs dual vs triple: Mono = 1 receptor (semaglutide, GLP-1). Dual = 2 (tirzepatide, GIP+GLP-1). Triple = 3 (retatrutide, GIP+GLP-1+glucagon).
Why acylation matters for identity: Triagonists are acylated (fatty diacid) for a ~6-day half-life; the acylated species must be confirmed by ESI-MS, not HPLC purity alone.
Regulatory / RUO status: Retatrutide is investigational (no FDA approval). Titan's product is a research-use-only reagent, not for human or animal use. No efficacy claim.

Questions researchers ask

Before you order.

What is a triple agonist?: A triple agonist is a single molecule engineered to bind and activate three different receptors simultaneously. 'Agonist' means it switches a receptor on; 'triple' means it does so for three receptors at once (also called a unimolecular triagonist). In peptide and metabolic research the term almost always refers to compounds that activate the GIP, GLP-1, and glucagon receptors together. The defining example is retatrutide (LY3437943), described as a triple GCGR/GIPR/GLP-1R agonist by Coskun et al. (Cell Metab. 2022;34:1234-1247, PMID 35985340). These are investigational compounds; research-use-only reagents, not for human use.
What is a triple-agonist peptide, and which peptide is the main example?: A triple-agonist peptide is a single acylated peptide that activates three metabolic receptors — the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The canonical example, and the compound the term was effectively coined around, is retatrutide (LY3437943, Eli Lilly's discovery designation). It was first characterised pharmacologically by Coskun et al. in Cell Metabolism (2022) and then studied in a published Phase 2 human obesity trial (Jastreboff et al., NEJM 2023;389:514-526, PMID 37366315). Other experimental triagonists exist in the literature, but retatrutide is the one with the most published human data.
How is a triple agonist different from a mono- or dual-agonist?: The difference is simply how many receptors the single molecule engages. A mono-agonist activates one receptor — semaglutide acts on the GLP-1 receptor only. A dual-agonist (co-agonist) activates two — tirzepatide acts on the GIP and GLP-1 receptors. A triple agonist activates three — retatrutide adds the glucagon receptor to GIP and GLP-1. The added glucagon-receptor arm is studied for increasing energy expenditure (thermogenesis), whereas the GLP-1 and GIP arms mainly reduce appetite and improve insulin handling. In published trials, more receptor arms broadly corresponded to larger weight changes, though these are clinical benchmarks for the drug class, not claims about a research reagent.
Why do the three receptors in a metabolic triple agonist matter?: Each receptor contributes a distinct effect. The GLP-1 receptor arm suppresses appetite and slows gastric emptying. The GIP receptor arm — the dominant driver of the natural 'incretin effect' in humans (Nauck & Meier, Diabetes Obes Metab. 2018;20 Suppl 1:5-21) — augments glucose-dependent insulin secretion and adipose insulin sensitivity. The glucagon receptor arm is studied for stimulating thermogenesis in brown adipose tissue and raising metabolic rate (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037). Combining all three in one molecule is intended to pair reduced caloric intake with potentially increased caloric expenditure.
Is a triple agonist FDA-approved?: No. The leading metabolic triple agonist, retatrutide (LY3437943), remains an investigational compound as of 2026 — only Phase 2 data have been published and Phase 3 trials are ongoing. No triple-receptor agonist is FDA-approved for any indication (approved incretin drugs are mono-agonists like semaglutide or the dual-agonist tirzepatide). Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory use — not for human or animal administration. Trial data referenced here is published science for context, not a claim about what Titan's product does, and not medical advice.